Fig. 2From: Trial protocol for a multicenter randomized controlled trial to assess the efficacy and safety of intravenous ketamine for chronic daily headaches: the “KetHead” trialSchedule of enrollment, interventions, and assessments. -t1, 28 days before infusion; 0: day of infusion; t1, end of infusion; t2, at 7 days post-infusion; t3, at 28 days post-infusion; t4, at 56 days post-infusion; t5, at 84 days post-infusionBack to article page